Drugs / budesonide/formoterol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03478683 | Jun 2018 → Mar 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent viatris.com ↗ |
| 2021-03-08 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol viatris.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | budesonide/formoterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03478683 ↗ |
| Known as | Symbicort | “Symbicort Metered Dose Inhaler (MDI) (budesonide/formoterol 320/9 mcg)” NCT03478683 ↗ |
| Route | Inhaled | “two inhalations of budesonide/formoterol via MDI” NCT03478683 ↗ |